Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Regeneron boosts growth with strong Dupixent sales and FDA approval of Pasatru.

REGN

$812.00

-$21.56 -2.59%

Regeneron boosts growth with strong Dupixent sales and FDA approval of Pasatru.

Analyst Insights

25 Aug 2026

Seeking Alpha

View Source

Bullish

Regeneron Pharmaceuticals ended August positively as its Dupixent sales surged to €5.15 billion in Q2, up 23.6% sequentially, offsetting declines in Eylea sales due to biosimilar competition. Additionally, the FDA approved Pasatru on August 19 for treating fibrodysplasia ossificans progressiva, a rare genetic condition. These developments reinforce Regeneron's strong position in the immunology market and suggest continued growth potential despite challenges in other product lines.

More News (REGN)

Regeneron adopts Veeva Vault CRM to boost AI-driven commercial insights and treatment access.

Regeneron Pharmaceuticals has chosen Veeva Vault CRM globally to enhance its commercial operations by generating Commercial Evidence through AI-powered field engagement. This platform will help Regeneron's commercial teams access critical information...

Market News

Bullish

2 days ago